Ting Julie Anne, Induruwage Dilshani, Yoshida Eric M, Dhruve Miten, Zalunardo Nadia Y
Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada.
British Columbia Renal Agency, Vancouver, British Columbia, Canada.
Can Liver J. 2023 Feb 28;6(1):2-13. doi: 10.3138/canlivj-2022-0019. eCollection 2023 Feb.
Albuminuria is a marker of chronic kidney disease (CKD) associated with an increased risk of end-stage kidney disease (ESKD) and mortality in the general population, but it is uncertain whether the same association exists in liver transplant (LT) recipients. This study examined the association between albuminuria and kidney failure and mortality in LT recipients. Retrospective cohort study of 294 adults who received a LT between January 1, 1989, and December 31, 2011, in British Columbia, Canada. Cox multivariable regression was used to determine the association between ACR and a primary combined outcome of mortality, doubling of serum creatinine, or ESKD; and a secondary outcome of a decrease in estimated glomerular filtration rate (eGFR) ≥30%. At baseline, mean eGFR was 67 (SD 20.9) mL/min/1.73 m, and 10% had severe albuminuria (ACR >30 mg/mmol). The primary outcome occurred in 20.4% (60) of patients and was associated with ACR >30 mg/mmol (HR 2.77, 95% CI 1.28-6.04; = 0.01). A decline in eGFR ≥30% occurred in 21.8% (64) of patients, and was associated with ACR >30 mg/mmol (HR 4.77, 95% CI 2.31-9.86; < 0.0001). Severe albuminuria (ACR >30 mg/mmol) was associated with an increased risk of loss of kidney function and mortality after LT. Prospective studies are needed to determine if specific interventions directed at reducing albuminuria can improve long-term outcomes in LT recipients.
蛋白尿是慢性肾脏病(CKD)的一个标志物,与普通人群终末期肾病(ESKD)风险增加及死亡率升高相关,但在肝移植(LT)受者中是否存在同样的关联尚不确定。本研究探讨了LT受者中蛋白尿与肾衰竭及死亡率之间的关联。对1989年1月1日至2011年12月31日期间在加拿大不列颠哥伦比亚接受LT的294名成年人进行回顾性队列研究。采用Cox多变量回归来确定尿白蛋白肌酐比值(ACR)与死亡率、血清肌酐翻倍或ESKD的主要联合结局之间的关联;以及与估计肾小球滤过率(eGFR)下降≥30%的次要结局之间的关联。基线时,平均eGFR为67(标准差20.9)ml/min/1.73 m²,10%的患者有严重蛋白尿(ACR>30 mg/mmol)。20.4%(60例)的患者出现主要结局,且与ACR>30 mg/mmol相关(风险比2.77,95%置信区间1.28 - 6.04;P = 0.01)。21.8%(64例)的患者eGFR下降≥30%,且与ACR>30 mg/mmol相关(风险比4.77,95%置信区间2.31 - 9.86;P < 0.0001)。严重蛋白尿(ACR>30 mg/mmol)与LT后肾功能丧失及死亡风险增加相关。需要进行前瞻性研究以确定针对降低蛋白尿的特定干预措施是否能改善LT受者的长期结局。